Which has stronger earnings and valuation, CV or AORT?

Artivion has higher revenue and earnings than CapsoVision. CapsoVision is trading at a lower price-to-earnings ratio than Artivion, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CapsoVision $13.56M 24.94 -$25.32M -$2.34 N/A Artivion $441.33M 2.89 $9.77M $0.24 109.43

Does the media refer more to CV or AORT?

In the previous week, Artivion had 4 more articles in the media than CapsoVision. MarketBeat recorded 6 mentions for Artivion and 2 mentions for CapsoVision. Artivion's average media sentiment score of 1.03 beat CapsoVision's score of 0.00 indicating that Artivion is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CapsoVision 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Artivion 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer IART or CV?

In the previous week, Integra LifeSciences had 13 more articles in the media than CapsoVision. MarketBeat recorded 15 mentions for Integra LifeSciences and 2 mentions for CapsoVision. Integra LifeSciences' average media sentiment score of 0.70 beat CapsoVision's score of 0.00 indicating that Integra LifeSciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Integra LifeSciences 8 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive CapsoVision 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to CV or STAA?

In the previous week, STAAR Surgical had 8 more articles in the media than CapsoVision. MarketBeat recorded 10 mentions for STAAR Surgical and 2 mentions for CapsoVision. STAAR Surgical's average media sentiment score of 0.23 beat CapsoVision's score of 0.00 indicating that STAAR Surgical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CapsoVision 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral STAAR Surgical 1 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings and valuation, IRMD or CV?

iRadimed has higher revenue and earnings than CapsoVision. CapsoVision is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio iRadimed $83.81M 14.02 $22.48M $1.79 51.32 CapsoVision $13.56M 24.94 -$25.32M -$2.34 N/A

Is IRMD or CV more profitable?

iRadimed has a net margin of 26.70% compared to CapsoVision's net margin of -198.87%. iRadimed's return on equity of 23.45% beat CapsoVision's return on equity. Company Net Margins Return on Equity Return on Assets iRadimed 26.70% 23.45% 20.36% CapsoVision -198.87% N/A -136.03%

Does the media prefer IRMD or CV?

In the previous week, iRadimed had 14 more articles in the media than CapsoVision. MarketBeat recorded 16 mentions for iRadimed and 2 mentions for CapsoVision. iRadimed's average media sentiment score of 0.54 beat CapsoVision's score of 0.00 indicating that iRadimed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment iRadimed 2 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CapsoVision 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings & valuation, CV or BVS?

Bioventus has higher revenue and earnings than CapsoVision. CapsoVision is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CapsoVision $13.56M 24.94 -$25.32M -$2.34 N/A Bioventus $568.09M 2.24 $22.73M $0.41 37.22

Is CV or BVS more profitable?

Bioventus has a net margin of 4.94% compared to CapsoVision's net margin of -198.87%. Bioventus' return on equity of 29.97% beat CapsoVision's return on equity. Company Net Margins Return on Equity Return on Assets CapsoVision -198.87% N/A -136.03% Bioventus 4.94% 29.97% 9.52%

Does the media refer more to CV or BVS?

In the previous week, Bioventus had 11 more articles in the media than CapsoVision. MarketBeat recorded 13 mentions for Bioventus and 2 mentions for CapsoVision. Bioventus' average media sentiment score of 0.33 beat CapsoVision's score of 0.00 indicating that Bioventus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CapsoVision 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Bioventus 2 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

CapsoVision (CV) Competitors

$6.77 -0.17 (-2.45%)

Closing price 08/5/2026 04:00 PM Eastern

Extended Trading

$6.77 0.00 (0.00%)

As of 08/5/2026 07:34 PM Eastern

Compare

CV vs. AORT, IART, STAA, IRMD, and BVS

Should you buy CapsoVision stock or one of its competitors? MarketBeat compares CapsoVision with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with CapsoVision include Artivion (AORT), Integra LifeSciences (IART), STAAR Surgical (STAA), iRadimed (IRMD), and Bioventus (BVS). These companies are all part of the "healthcare equipment" industry.

How does CapsoVision compare to Artivion?

CapsoVision (NASDAQ:CV) and Artivion (NYSE:AORT) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings, valuation and media sentiment.

Artivion has a net margin of 2.55% compared to CapsoVision's net margin of -198.87%. Artivion's return on equity of 7.15% beat CapsoVision's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CapsoVision	-198.87%	N/A	-136.03%
Artivion	2.55%	7.15%	3.63%

CapsoVision currently has a consensus target price of $8.50, indicating a potential upside of 25.55%. Artivion has a consensus target price of $44.17, indicating a potential upside of 68.18%. Given Artivion's stronger consensus rating and higher probable upside, analysts plainly believe Artivion is more favorable than CapsoVision.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CapsoVision	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Artivion	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

86.4% of Artivion shares are owned by institutional investors. 2.3% of CapsoVision shares are owned by company insiders. Comparatively, 6.3% of Artivion shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Artivion has higher revenue and earnings than CapsoVision. CapsoVision is trading at a lower price-to-earnings ratio than Artivion, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CapsoVision	$13.56M	24.94	-$25.32M	-$2.34	N/A
Artivion	$441.33M	2.89	$9.77M	$0.24	109.43

In the previous week, Artivion had 4 more articles in the media than CapsoVision. MarketBeat recorded 6 mentions for Artivion and 2 mentions for CapsoVision. Artivion's average media sentiment score of 1.03 beat CapsoVision's score of 0.00 indicating that Artivion is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CapsoVision	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Artivion	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Artivion beats CapsoVision on 14 of the 16 factors compared between the two stocks.

How does CapsoVision compare to Integra LifeSciences?

Integra LifeSciences (NASDAQ:IART) and CapsoVision (NASDAQ:CV) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, media sentiment, analyst recommendations, earnings and risk.

Integra LifeSciences has a net margin of -0.44% compared to CapsoVision's net margin of -198.87%. Integra LifeSciences' return on equity of 18.30% beat CapsoVision's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Integra LifeSciences	-0.44%	18.30%	5.30%
CapsoVision	-198.87%	N/A	-136.03%

CapsoVision has lower revenue, but higher earnings than Integra LifeSciences. Integra LifeSciences is trading at a lower price-to-earnings ratio than CapsoVision, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Integra LifeSciences	$1.64B	0.84	-$516.47M	-$0.09	N/A
CapsoVision	$13.56M	24.94	-$25.32M	-$2.34	N/A

84.8% of Integra LifeSciences shares are owned by institutional investors. 3.8% of Integra LifeSciences shares are owned by company insiders. Comparatively, 2.3% of CapsoVision shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Integra LifeSciences currently has a consensus target price of $18.86, indicating a potential upside of 6.66%. CapsoVision has a consensus target price of $8.50, indicating a potential upside of 25.55%. Given CapsoVision's stronger consensus rating and higher possible upside, analysts clearly believe CapsoVision is more favorable than Integra LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Integra LifeSciences	2 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.88
CapsoVision	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

In the previous week, Integra LifeSciences had 13 more articles in the media than CapsoVision. MarketBeat recorded 15 mentions for Integra LifeSciences and 2 mentions for CapsoVision. Integra LifeSciences' average media sentiment score of 0.70 beat CapsoVision's score of 0.00 indicating that Integra LifeSciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Integra LifeSciences	8 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
CapsoVision	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Integra LifeSciences beats CapsoVision on 9 of the 15 factors compared between the two stocks.

How does CapsoVision compare to STAAR Surgical?

CapsoVision (NASDAQ:CV) and STAAR Surgical (NASDAQ:STAA) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, profitability, analyst recommendations, valuation and media sentiment.

STAAR Surgical has a net margin of -7.24% compared to CapsoVision's net margin of -198.87%. STAAR Surgical's return on equity of 3.31% beat CapsoVision's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CapsoVision	-198.87%	N/A	-136.03%
STAAR Surgical	-7.24%	3.31%	2.55%

CapsoVision has higher earnings, but lower revenue than STAAR Surgical. STAAR Surgical is trading at a lower price-to-earnings ratio than CapsoVision, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CapsoVision	$13.56M	24.94	-$25.32M	-$2.34	N/A
STAAR Surgical	$239.44M	4.75	-$80.45M	-$0.43	N/A

CapsoVision currently has a consensus price target of $8.50, indicating a potential upside of 25.55%. STAAR Surgical has a consensus price target of $26.94, indicating a potential upside of 17.87%. Given CapsoVision's stronger consensus rating and higher possible upside, equities analysts clearly believe CapsoVision is more favorable than STAAR Surgical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CapsoVision	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
STAAR Surgical	3 Sell rating(s)	6 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.00

96.7% of STAAR Surgical shares are owned by institutional investors. 2.3% of CapsoVision shares are owned by insiders. Comparatively, 39.9% of STAAR Surgical shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, STAAR Surgical had 8 more articles in the media than CapsoVision. MarketBeat recorded 10 mentions for STAAR Surgical and 2 mentions for CapsoVision. STAAR Surgical's average media sentiment score of 0.23 beat CapsoVision's score of 0.00 indicating that STAAR Surgical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CapsoVision	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
STAAR Surgical	1 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

STAAR Surgical beats CapsoVision on 10 of the 16 factors compared between the two stocks.

How does CapsoVision compare to iRadimed?

iRadimed (NASDAQ:IRMD) and CapsoVision (NASDAQ:CV) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, dividends, risk, media sentiment, analyst recommendations and earnings.

iRadimed has a net margin of 26.70% compared to CapsoVision's net margin of -198.87%. iRadimed's return on equity of 23.45% beat CapsoVision's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iRadimed	26.70%	23.45%	20.36%
CapsoVision	-198.87%	N/A	-136.03%

92.3% of iRadimed shares are held by institutional investors. 34.6% of iRadimed shares are held by company insiders. Comparatively, 2.3% of CapsoVision shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

iRadimed pays an annual dividend of $0.80 per share and has a dividend yield of 0.9%. CapsoVision pays an annual dividend of $0.92 per share and has a dividend yield of 13.6%. iRadimed pays out 44.7% of its earnings in the form of a dividend. CapsoVision pays out -39.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. iRadimed has increased its dividend for 1 consecutive years. CapsoVision is clearly the better dividend stock, given its higher yield and lower payout ratio.

iRadimed has higher revenue and earnings than CapsoVision. CapsoVision is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iRadimed	$83.81M	14.02	$22.48M	$1.79	51.32
CapsoVision	$13.56M	24.94	-$25.32M	-$2.34	N/A

iRadimed currently has a consensus target price of $120.00, indicating a potential upside of 30.63%. CapsoVision has a consensus target price of $8.50, indicating a potential upside of 25.55%. Given iRadimed's stronger consensus rating and higher probable upside, equities research analysts clearly believe iRadimed is more favorable than CapsoVision.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iRadimed	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.80
CapsoVision	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

In the previous week, iRadimed had 14 more articles in the media than CapsoVision. MarketBeat recorded 16 mentions for iRadimed and 2 mentions for CapsoVision. iRadimed's average media sentiment score of 0.54 beat CapsoVision's score of 0.00 indicating that iRadimed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iRadimed	2 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CapsoVision	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

iRadimed beats CapsoVision on 15 of the 18 factors compared between the two stocks.

How does CapsoVision compare to Bioventus?

CapsoVision (NASDAQ:CV) and Bioventus (NASDAQ:BVS) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, media sentiment, earnings and dividends.

Bioventus has a net margin of 4.94% compared to CapsoVision's net margin of -198.87%. Bioventus' return on equity of 29.97% beat CapsoVision's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CapsoVision	-198.87%	N/A	-136.03%
Bioventus	4.94%	29.97%	9.52%

Bioventus has higher revenue and earnings than CapsoVision. CapsoVision is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CapsoVision	$13.56M	24.94	-$25.32M	-$2.34	N/A
Bioventus	$568.09M	2.24	$22.73M	$0.41	37.22

62.9% of Bioventus shares are owned by institutional investors. 2.3% of CapsoVision shares are owned by company insiders. Comparatively, 33.5% of Bioventus shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

CapsoVision presently has a consensus target price of $8.50, suggesting a potential upside of 25.55%. Bioventus has a consensus target price of $14.75, suggesting a potential downside of 3.34%. Given CapsoVision's higher probable upside, equities research analysts plainly believe CapsoVision is more favorable than Bioventus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CapsoVision	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Bioventus	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.00

In the previous week, Bioventus had 11 more articles in the media than CapsoVision. MarketBeat recorded 13 mentions for Bioventus and 2 mentions for CapsoVision. Bioventus' average media sentiment score of 0.33 beat CapsoVision's score of 0.00 indicating that Bioventus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CapsoVision	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Bioventus	2 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Bioventus beats CapsoVision on 13 of the 15 factors compared between the two stocks.

Get CapsoVision News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CV vs. The Competition

Export

Metric	CapsoVision	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$346.75M	$5.82B	$6.87B	$12.98B
Dividend Yield	N/A	1.78%	2.60%	9.79%
P/E Ratio	-2.89	23.49	280.35	25.25
Price / Sales	24.94	58.67	604.25	94.30
Price / Cash	N/A	32.67	71.79	50.79
Price / Book	24.18	6.12	12.97	6.09
Net Income	-$25.32M	$151.74M	$3.49B	$347.95M
7 Day Performance	1.04%	3.51%	2.41%	3.11%
1 Month Performance	2.42%	-1.63%	-2.87%	-2.99%
1 Year Performance	60.43%	8.95%	75.29%	20.51%

CapsoVision Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CV CapsoVision	1.8951 of 5 stars	$6.77 -2.4%	$8.50 +25.6%	+63.5%	$346.75M	$13.56M	N/A	90
AORT Artivion	4.3655 of 5 stars	$27.54 +2.7%	$44.17 +60.4%	-18.2%	$1.30B	$441.33M	41.28	1,800	Positive News
IART Integra LifeSciences	1.7778 of 5 stars	$17.88 +7.4%	$18.86 +5.5%	+38.9%	$1.29B	$1.64B	N/A	4,427
STAA STAAR Surgical	3.4477 of 5 stars	$24.34 -0.1%	$26.94 +10.7%	-15.4%	$1.21B	$239.44M	N/A	1,211	Trending News Upcoming Earnings Analyst Forecast
IRMD iRadimed	2.8294 of 5 stars	$91.56 +0.8%	$120.00 +31.1%	+32.0%	$1.16B	$83.81M	51.15	110	Earnings Report Dividend Announcement Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CV) was last updated on 8/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CapsoVision (CV) Competitors

CV vs. AORT, IART, STAA, IRMD, and BVS

How does CapsoVision compare to Artivion?

Summary

How does CapsoVision compare to Integra LifeSciences?

Summary

How does CapsoVision compare to STAAR Surgical?

Summary

How does CapsoVision compare to iRadimed?

Summary

How does CapsoVision compare to Bioventus?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CV vs. The Competition

CapsoVision Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CapsoVision (CV) Competitors

CV vs. AORT, IART, STAA, IRMD, and BVS

How does CapsoVision compare to Artivion?

Is CV or AORT more profitable?

Do analysts rate CV or AORT?

Do insiders and institutionals have more ownership in CV or AORT?

Which has stronger earnings and valuation, CV or AORT?

Does the media refer more to CV or AORT?

Summary

How does CapsoVision compare to Integra LifeSciences?

Is IART or CV more profitable?

Which has stronger earnings and valuation, IART or CV?

Do insiders & institutionals believe in IART or CV?

Do analysts rate IART or CV?

Does the media prefer IART or CV?

Summary

How does CapsoVision compare to STAAR Surgical?

Is CV or STAA more profitable?

Which has stronger valuation & earnings, CV or STAA?

Do analysts prefer CV or STAA?

Do insiders and institutionals believe in CV or STAA?

Does the media refer more to CV or STAA?

Summary

How does CapsoVision compare to iRadimed?

Is IRMD or CV more profitable?

Do insiders & institutionals have more ownership in IRMD or CV?

Is IRMD or CV a better dividend stock?

Which has higher earnings and valuation, IRMD or CV?

Do analysts recommend IRMD or CV?

Does the media prefer IRMD or CV?

Summary

How does CapsoVision compare to Bioventus?

Is CV or BVS more profitable?

Which has higher earnings & valuation, CV or BVS?

Do insiders and institutionals have more ownership in CV or BVS?

Do analysts recommend CV or BVS?

Does the media refer more to CV or BVS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CV vs. The Competition

CapsoVision Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools